http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-545366-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10d466a9fac96c33267bd561843b72f3 |
| filingDate | 2002-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_811b1320475692a82a01ee0e8b18fbd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aef4c6fa943e0879ae710ff730655cd3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5ddfda01468538b2b4511be47131c47 |
| publicationDate | 2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-545366-A |
| titleOfInvention | Glutaminyl based DPIV inhibitors |
| abstract | An acid addition salt of a compound of the formula (I) is disclosed: wherein X = CH2 or S; and wherein the acid addition salt is selected from the group consisting of salts of hydrobromic, perchioric, nitric, propionic, glycolic, lactic, maleic, malic, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic and trifluoroacetic acid. The pharmaceutically acceptable acid addition salt forms of the compound of the formula (I) are useful in treating conditions mediated by dipeptidyl peptidase IV (DPIV) or DPIV-like enzymes, such as arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases. |
| priorityDate | 2002-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 330.